Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Inogen Inc filings on SEC EDGAR ↗
Inogen Inc. reported a net loss of $16.2 million for the third quarter of 2026, compared to a $5.3 million loss in the prior year, driven by a $10.6 million impairment charge. Total revenue for the quarter decreased slightly to $77.2 million, while the company's cash position declined to $81.8 million as of September 30, 2026.
Inogen is undergoing a strategic pivot, divesting its rental business and implementing a $20 million cost reduction program to offset international softness and return to profitability.
Inogen appointed current COO Andy Reding as President and CEO and a member of the Board of Directors, effective October 30, 2026. He succeeds Kevin R.M. Smith, whose role as an officer and employee ended on the same date. The transition occurs as the company focuses on a more streamlined commercial model following the divestiture of its U.S. rental business.
Inogen Divestiture to Rotech Healthcare Inc. for $24.8M
Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare for an estimated $24.8 million. The divestiture is intended to streamline Inogen's commercial model and shift focus toward its product supply business, supported by a new long-term supply agreement with Rotech. Upon closing, Inogen will also increase its share repurchase authorization from $30 million to $45 million.